The PAC Industry Presents

Traditional vs Novel Psychedelics

November 29, 2023

Join Clearmind Medicine CEO, Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, as they discuss Traditional vs. Novel psychedelics, and other issues related to the growing and changing international psychedelic space.


Rick Doblin, PhD

Founder MAPS

Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS). His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist.

Adi Zuloff-Shani, PhD

Clearmind's Chief Executive Officer

Dr. Adi Zuloff-Shani is a biomedical research and development executive with over 20 years of strategic and operational leadership in the healthcare industry, and a deep understanding of therapeutics development in heavily regulated environments.

Adjunct Prof. Mark Haden

Clearmind's VP of Business Development

Previously the Executive Director of MAPS Canada for 10 years, Mark is an adjunct professor at the University of British Columbia's School of Population and Public Health, and has published on the issue of drug control policy and psychedelics. Mark also worked in the addictions field in counselling, supervisory and management positions for 28 years.


Gillian Maxwell

PAC Board Member

Based in BC, Canada, Gillian brings her experience in harm reduction and drug policy reform, along with a wide and diverse network of colleagues and associates, who value her knowledge and wisdom. She co-founded the Canadian Drug Policy Coalition (CDPC), served on the board of directors of MAPS Canada for over 10 years, has spoken at conferences nationally and internationally. In 2012, Gillian received Queen Elizabeth II, Diamond Jubilee Medal, for community service in introducing harm reduction to Vancouver.